JP5947906B2 - ２−ピリジルオキシ−４−ニトリルオレキシン受容体アンタゴニスト - Google Patents

２−ピリジルオキシ−４−ニトリルオレキシン受容体アンタゴニスト Download PDF

Info

Publication number
JP5947906B2
JP5947906B2 JP2014537157A JP2014537157A JP5947906B2 JP 5947906 B2 JP5947906 B2 JP 5947906B2 JP 2014537157 A JP2014537157 A JP 2014537157A JP 2014537157 A JP2014537157 A JP 2014537157A JP 5947906 B2 JP5947906 B2 JP 5947906B2
Authority
JP
Japan
Prior art keywords
oxy
carbonitrile
pyridine
carbonyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014537157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532624A (ja
Inventor
クダツク，スコツト，デイー
スクドラレク，ジエイソン，ダブリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2014532624A publication Critical patent/JP2014532624A/ja
Application granted granted Critical
Publication of JP5947906B2 publication Critical patent/JP5947906B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014537157A 2011-10-19 2012-10-17 ２−ピリジルオキシ−４−ニトリルオレキシン受容体アンタゴニスト Expired - Fee Related JP5947906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548883P 2011-10-19 2011-10-19
US61/548,883 2011-10-19
PCT/US2012/060479 WO2013059222A1 (en) 2011-10-19 2012-10-17 2-pyridyloxy-4-nitrile orexin receptor antagonists

Publications (2)

Publication Number Publication Date
JP2014532624A JP2014532624A (ja) 2014-12-08
JP5947906B2 true JP5947906B2 (ja) 2016-07-06

Family

ID=47116466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537157A Expired - Fee Related JP5947906B2 (ja) 2011-10-19 2012-10-17 ２−ピリジルオキシ−４−ニトリルオレキシン受容体アンタゴニスト

Country Status (11)

Country Link
US (1) US9156819B2 (enExample)
EP (1) EP2768823B1 (enExample)
JP (1) JP5947906B2 (enExample)
CN (1) CN103874695B (enExample)
AR (1) AR088352A1 (enExample)
AU (1) AU2012326275B2 (enExample)
BR (1) BR112014009486A2 (enExample)
CA (1) CA2852425C (enExample)
IN (1) IN2014CN02515A (enExample)
TW (1) TW201317228A (enExample)
WO (1) WO2013059222A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220065A (zh) 2012-02-07 2014-12-17 Eolas治疗公司 取代的脯氨酸/哌啶用作食欲素受体拮抗剂
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2014062533A1 (en) * 2012-10-16 2014-04-24 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists
US9546152B2 (en) * 2012-10-23 2017-01-17 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
US9624197B2 (en) 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2934517A4 (en) * 2012-12-20 2016-05-25 Merck Sharp & Dohme 2-PYRIDYLOXY-3-NITRIL-4-SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
US9556145B2 (en) * 2012-12-20 2017-01-31 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-ester orexin receptor antagonists
US9765057B2 (en) * 2012-12-20 2017-09-19 Merck Sharp & Dohme Corp. 3-ester-4 substituted orexin receptor antagonists
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
US9725434B2 (en) * 2013-04-23 2017-08-08 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
WO2015018027A1 (en) 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
WO2015018029A1 (en) * 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
US9975876B2 (en) 2013-12-09 2018-05-22 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
WO2015088865A1 (en) 2013-12-09 2015-06-18 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-methyl orexin receptor antagonists
US9617246B2 (en) 2013-12-18 2017-04-11 Merck Sharp & Dohme Corp. Thioether-piperidinyl orexin receptor antagonists
WO2015095441A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-amino-3-ester-pyridyl orexin receptor antagonists
WO2015131773A1 (zh) * 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016065585A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Piperidine isoxazole and isothiazole orexin receptor antagonists
WO2016065586A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole, triazole and tetrazole orexin receptor antagonists
WO2016065583A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
WO2016065584A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Piperidine oxadiazole and thiadiazole orexin receptor antagonists
WO2016065587A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole orexin receptor antagonists
WO2016083315A1 (en) * 2014-11-24 2016-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
US9994570B2 (en) 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
WO2016085784A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
WO2016086357A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
WO2016086358A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxymethyl piperidine orexin receptor antagonists
WO2016100161A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Ethyldiamine orexin receptor antagonists
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016100162A2 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 5,5-bicyclic oxazole orexin receptor antagonists
WO2016095204A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor antagonists
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
WO2016101118A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Amidoethyl azole orexin receptor antagonists
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
WO2017088759A1 (en) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SMT202200323T1 (it) 2016-02-12 2022-09-14 Astrazeneca Ab Piperidine alo-sostituite come modulatori del recettore di oressina
US20190151304A1 (en) 2016-05-10 2019-05-23 Inserm (Institut National De La Santé Et De La Rechercjae Médicale Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
TWI790264B (zh) 2017-08-03 2023-01-21 日商武田藥品工業股份有限公司 雜環化合物及其用途

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
CA1258454A (en) 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
IT1159765B (it) 1982-09-28 1987-03-04 Zanussi A Spa Industrie Macchina lavabiancheria di tipo modulare
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
DE69220258T2 (de) 1991-02-11 1997-12-18 Merck Sharp & Dohme Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
DE69200921T2 (de) 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
US5459270A (en) 1991-08-20 1995-10-17 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
GB9211193D0 (en) 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5637699A (en) 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
US5496833A (en) 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
JP3386814B2 (ja) 1994-11-07 2003-03-17 ファイザー・インコーポレーテッド ある種の置換ベンジルアミン誘導体：新種の神経ペプチドｙ１特異的リガンド
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
AU7692696A (en) 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6017919A (en) 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CA2273102A1 (en) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Urea derivatives
AU5410498A (en) 1996-12-12 1998-07-03 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
CA2274593A1 (en) 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
US6180653B1 (en) 1996-12-16 2001-01-30 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
DE69822449T2 (de) 1997-01-21 2005-01-27 Smithkline Beecham Corp. Neue cannabinoidrezeptor-modulatoren
CN1982290A (zh) 1997-02-04 2007-06-20 阿肯色大学评议会 杀菌的羧酰胺
CN100453529C (zh) 1997-02-21 2009-01-21 拜尔公司 芳基磺酰胺及其类似物及其在治疗神经变性疾病中的用途
WO1998040356A1 (en) 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
CA2283797A1 (en) 1997-03-18 1998-09-24 Paul Elliot Bender Novel cannabinoid receptor agonists
FR2761265B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
EP0992239B1 (en) 1997-04-23 2003-03-12 Banyu Pharmaceutical Co., Ltd. Neuropeptide y receptor antagonist
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
AU8127998A (en) 1997-07-11 1999-02-08 Japan Tobacco Inc. Quinoline compounds and medicinal uses thereof
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
WO1999015516A1 (en) 1997-09-25 1999-04-01 Banyu Pharmaceutical Co., Ltd. Novel neuropeptide y receptor antagonists
AU1262199A (en) 1997-11-28 1999-06-16 Banyu Pharmaceutical Co., Ltd. Antihyperlipemic agents
EP1068207A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES
PT1076644E (pt) 1998-04-29 2004-10-29 Ortho Mcneil Pharm Inc Aminotetralinas substituidas emn como ligandos para o receptor de neuropeptideoy y5 util no tratamento da obesidade e de outras perturbacoes
JP4633925B2 (ja) 1998-05-08 2011-02-16 スミスクライン ビーチャム ピー エル シー フェニル尿素およびフェニルチオ尿素誘導体
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
ATE314371T1 (de) 1998-11-10 2006-01-15 Merck & Co Inc Spiro-indole als y5-rezeptor antagonisten
ATE274512T1 (de) 1999-02-12 2004-09-15 Smithkline Beecham Plc Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
JP2002536447A (ja) 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー フェニル尿素およびフェニルチオ尿素誘導体
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
JP2002543067A (ja) 1999-04-22 2002-12-17 シナプティック・ファーマスーティカル・コーポレーション 選択的なｎｐｙ（ｙ５）のアンタゴニスト
MXPA01011321A (es) 1999-05-05 2003-08-01 Johnson & Johnson Neuropeptidos y ligandos de receptores 3a, 4, 5, 9b-tetrahidro-1h-benz(e)indol-2-il amino derivados utiles en el tratamiento de obesidad y otros trastornos.
AU778393B2 (en) 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2001002379A1 (en) 1999-06-30 2001-01-11 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
US6462053B1 (en) 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2383147A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Mch antagonists
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU7738100A (en) 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
CZ20021089A3 (cs) 1999-09-30 2002-11-13 Neurogen Corporation Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
ES2243337T3 (es) 1999-12-16 2005-12-01 Schering Corporation Imidazoles sustituidos antagonistas del receptor y5 del neuropeptido y.
CN1395575A (zh) 2000-01-20 2003-02-05 卫材株式会社 新的哌啶化合物及其药物
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
CA2400659A1 (en) 2000-02-22 2001-08-30 Banyu Pharmaceutical Co., Ltd. Novel imidazoline compounds
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
CN100393703C (zh) 2000-03-14 2008-06-11 埃科特莱茵药品有限公司 1,2,3,4-四氢异喹啉的衍生物
EP1142886A1 (en) 2000-04-07 2001-10-10 Aventis Pharma Deutschland GmbH Percyquinnin, a process for its production and its use as a pharmaceutical
DE60142961D1 (de) 2000-04-28 2010-10-14 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
AU2001263021A1 (en) 2000-05-10 2001-11-20 Bristol-Myers Squibb Company Alkylamine derivatives of dihydropyridine npy antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
JPWO2001085693A1 (ja) 2000-05-11 2004-01-08 萬有製薬株式会社 Ｎ−アシルテトラヒドロイソキノリン誘導体
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
AU783403B2 (en) 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
AU2001279294A1 (en) 2000-07-06 2002-01-21 Neurogen Corporation Melanin concentrating hormone receptor ligands
US20020187938A1 (en) 2000-07-24 2002-12-12 Romano Deghenghi Ghrelin antagonists
AU2001283955B2 (en) 2000-07-31 2006-05-18 F. Hoffmann-La Roche Ag Piperazine derivatives
HK1054547A1 (zh) 2000-09-14 2003-12-05 Schering Corporation 取代的脲神经肽yy5受体拮抗剂
ATE270280T1 (de) 2000-10-13 2004-07-15 Lilly Co Eli Substituierte dipeptide zur förderung der sekretion von wachstumshormon
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ．ホフマン−ラ ロシュ アーゲー インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
WO2002036596A2 (en) 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
NZ525699A (en) 2000-11-20 2005-03-24 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
PL361690A1 (en) 2000-11-20 2004-10-04 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
ATE286897T1 (de) 2000-11-28 2005-01-15 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
ES2249384T3 (es) 2000-12-12 2006-04-01 Neurogen Corporation Espiro(isobenzofuran-1,4'-piperadin)-3-onas y 3h-espirobenzofuran-1,4-piperidinas.
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
AU2002234056B2 (en) 2000-12-21 2005-04-07 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
ES2243588T3 (es) 2000-12-22 2005-12-01 Schering Corporation Antagonistas piperidinicos de la mch y su uso en el tratamientyo de la obesidad.
DE60129841T2 (de) 2000-12-27 2008-04-17 Vernalis Research Ltd., Winnersh Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
CN1500080A (zh) 2001-02-02 2004-05-26 ����ҩƷ��ҵ��ʽ���� 稠合杂环化合物
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
HUP0400252A3 (en) 2001-03-21 2011-09-28 Pharmacopeia Drug Discovery Aryl and biaryl compounds having mch modulatory activity, pharmaceutical compositions containing them and process for producing them
RU2281941C2 (ru) 2001-03-22 2006-08-20 Солвей Фармасьютикалс Б.В. Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью
ATE460163T1 (de) 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AU2002341123A1 (en) 2001-05-05 2002-11-18 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
ES2299567T3 (es) 2001-05-05 2008-06-01 Smithkline Beecham Plc N-aroilaminas ciclicas.
FR2824825B1 (fr) 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0209932A (pt) 2001-05-22 2004-10-13 Neurogen Corp Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
AU2002310465B2 (en) 2001-06-20 2006-06-15 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
ATE381539T1 (de) 2001-06-20 2008-01-15 Merck & Co Inc Dipeptidylpeptidase-hemmer zur behandlung von diabetes
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
ATE374181T1 (de) 2001-06-27 2007-10-15 Smithkline Beecham Corp Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
US7196201B2 (en) 2001-06-27 2007-03-27 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
RU2003105463A (ru) 2001-06-27 2004-11-27 Пробиодруг Аг (De) Пептидные структуры, пригодные для конкурентного модулирования катализа, осуществляемого дипептидилпептидазой iv
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
EP1705179A1 (en) 2001-06-28 2006-09-27 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
ATE388951T1 (de) 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
MXPA03011886A (es) 2001-07-05 2005-03-07 Lundbeck & Co As H Piperidinias anilinicas sustituidas como antagonistas selectivos de mch.
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
BRPI0104510B8 (pt) 2001-07-27 2021-05-25 Embrapa Pesquisa Agropecuaria peptídeos antibióticos da família das phylloseptinas isolados da secreção da pele de phylloseptina hypocondrialis e composição antimicrobiana relacionada
MXPA04001144A (es) 2001-08-07 2004-07-08 Banyu Pharma Co Ltd Compuestos espiro.
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
JP2005320249A (ja) 2002-05-01 2005-11-17 Banyu Pharmaceut Co Ltd ２−アミノピラジン誘導体の製造方法
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN1556705B (zh) 2002-07-09 2010-04-28 埃科特莱茵药品有限公司 7,8,9,10-四氢-6H-氮杂卓并、6,7,8,9-四氢-吡啶并和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉酮衍生物
ATE344261T1 (de) 2002-09-18 2006-11-15 Glaxo Group Ltd Cyclische n-aroylamine als orexinrezeptorantagonisten
US6869966B2 (en) 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
JP2006504719A (ja) 2002-10-08 2006-02-09 メルク フロスト カナダ アンド カンパニー 骨粗しょう症の治療において有用なカテプシンｋ阻害剤としての４−アミノ−アゼパン−３−オン化合物
KR20050043988A (ko) 2002-10-11 2005-05-11 액테리온 파마슈티칼 리미티드 설포닐아미노-아세트산 유도체 및 오렉신 수용체길항제로서 이들의 용도
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
MY134457A (en) 2002-11-22 2007-12-31 Merck & Co Inc Substituted amides
WO2004052876A1 (en) 2002-12-12 2004-06-24 Janssen Pharmaceutica, N.V. Substituted 4-phenyl-[1,3]-dioxanes
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
ES2327737T3 (es) 2003-03-26 2009-11-03 Actelion Pharmaceuticals Ltd. Derivados de tetrahidroisoquinolil acetamida para uso como antagonistas de receptores de orexina.
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
DE602004011204T2 (de) 2003-04-28 2008-12-24 Actelion Pharmaceuticals Ltd. Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
WO2005000809A1 (en) 2003-06-11 2005-01-06 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
WO2006067224A2 (en) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
DE102004062544A1 (de) 2004-12-24 2006-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
CA2603766A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Amidopropoxyphenyl orexin receptor antagonists
JP2008536950A (ja) * 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
CA2609203A1 (en) 2005-05-23 2006-11-30 Merck & Co., Inc Proline bis-amide orexin receptor antagonists
CA2617324A1 (en) 2005-08-04 2007-02-15 Merck & Co., Inc. Aminoethane sulfonamide orexin receptor antagonists
JP2009506061A (ja) 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
AR055203A1 (es) * 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
AU2006316321A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
WO2007126934A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Amidoethylthioether orexin receptor antagonists
AU2007245037A1 (en) 2006-03-29 2007-11-08 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
EP2007717A1 (en) 2006-04-11 2008-12-31 Actelion Pharmaceuticals Ltd. Novel sulfonamide compounds
CA2647077A1 (en) 2006-04-26 2007-11-01 Actelion Pharmaceuticals Ltd Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
DK2049529T3 (da) 2006-07-14 2010-11-29 Merck Sharp & Dohme Substituerede diazepan-orexin-receptor- antagonister
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
JP2009543790A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド ２−置換プロリンビス−アミドオレキシン受容体アンタゴニスト
ATE500250T1 (de) 2006-08-15 2011-03-15 Actelion Pharmaceuticals Ltd Azetidinverbindungen als orexin-rezeptor- antagonisten
ES2339822T3 (es) 2006-08-28 2010-05-25 Actelion Pharmaceuticals Ltd. Derivados de 1,4,5,6,7,8-hexahidro-1,2,5-triaza-azuleno como antagonistas del receptor de orexina.
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
ES2357992T3 (es) * 2006-12-01 2011-05-04 Actelion Pharmaceuticals Ltd. Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina.
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
EP2131654A4 (en) * 2007-03-02 2011-02-02 Merck Sharp & Dohme Bipyridine-carboxamide-orexin receptor Antagonist
EP2152690B1 (en) 2007-05-23 2012-01-11 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2009020642A1 (en) * 2007-08-09 2009-02-12 Merck & Co., Inc. Pyridine carboxamide orexin receptor antagonists
AU2008340421B2 (en) * 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2318367B1 (en) 2008-04-30 2013-03-20 Actelion Pharmaceuticals Ltd. Piperidine and pyrrolidine compounds
CA2724648A1 (en) 2008-05-22 2009-11-26 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist
AU2009307915A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2349270B1 (en) 2008-10-21 2015-09-09 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
CA2739927A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
AU2009307920A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
US8357709B2 (en) 2008-10-21 2013-01-22 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
US8669272B2 (en) 2008-10-21 2014-03-11 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
NZ592544A (en) * 2008-10-30 2013-01-25 Merck Sharp & Dohme Isonicotinamide orexin receptor antagonists
US8399494B2 (en) * 2008-10-30 2013-03-19 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
US9546152B2 (en) * 2012-10-23 2017-01-17 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists

Also Published As

Publication number Publication date
US20130102619A1 (en) 2013-04-25
CN103874695A (zh) 2014-06-18
EP2768823A1 (en) 2014-08-27
CA2852425A1 (en) 2013-04-25
TW201317228A (zh) 2013-05-01
JP2014532624A (ja) 2014-12-08
US9156819B2 (en) 2015-10-13
AR088352A1 (es) 2014-05-28
CN103874695B (zh) 2017-12-15
AU2012326275A1 (en) 2014-04-17
EP2768823B1 (en) 2017-09-06
IN2014CN02515A (enExample) 2015-07-31
WO2013059222A1 (en) 2013-04-25
CA2852425C (en) 2019-11-12
BR112014009486A2 (pt) 2017-05-09
AU2012326275B2 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
JP5947906B2 (ja) ２−ピリジルオキシ−４−ニトリルオレキシン受容体アンタゴニスト
JP5635991B2 (ja) イソニコチンアミドオレキシン受容体アンタゴニスト
US9765057B2 (en) 3-ester-4 substituted orexin receptor antagonists
US9975876B2 (en) 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
US9643955B2 (en) 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
US9586950B2 (en) 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists
US9556145B2 (en) 2-pyridyloxy-4-ester orexin receptor antagonists
JP5639564B2 (ja) ピリジルピペリジン・オレキシン受容体アンタゴニスト
US9546152B2 (en) 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
US9624197B2 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
US9745284B2 (en) 2-pyridyloxy-4-ether orexin receptor antagonists
US9586934B2 (en) 2-pyridyloxy-4-methyl orexin receptor antagonists
US9556190B2 (en) Piperidinyloxy lactone orexin receptor antagonists
US10000499B2 (en) Methyl diazepane orexin receptor antagonists
US10227336B2 (en) Pyrazole orexin receptor antagonists
US20220144771A1 (en) Pyrrolidine orexin receptor agonists
JP2012506377A (ja) ２，４−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
JP2012507540A (ja) ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト
JP2012506376A (ja) ２，５−二置換モルホリンオレキシン受容体アンタゴニスト
JP2012506378A (ja) ２，３−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
JP2012507539A (ja) ２，５−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
US20160102073A1 (en) 2-hydroxymethyl-substituted orexin receptor antagonists
JP2012506374A (ja) ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
JP2012506379A (ja) 二置換アゼパンオレキシン受容体アンタゴニスト
JP2012506375A (ja) ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160603

R150 Certificate of patent or registration of utility model

Ref document number: 5947906

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees